TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy

Status Not yet recruiting

Clinical Trial Summary

The TIME study is a randomized, controlled trial to evaluate impact on early measures of neurodevelopment and the safety profile of therapeutic hypothermia in term neonates with Mild Hypoxic-Ischemic Encephalopathy who are < 6 hours of age. Neurodevelopmental outcome will be assessed at 12-14 months of age. The study will enroll 68 neonates randomized to therapeutic hypothermia or normothermia across 5 centers in California.

Clinical Trial Description

The TIME study is a multi-center randomized, controlled trial of Therapeutic Hypothermia (TH) (33.5°C ± 0.5° for 72 hours) versus normothermia using targeted temperature management, initiated within 6 hours after birth in term neonates with Mild Hypoxic-Ischemic Encephalopathy (HIE). Mild encephalopathy will be identified using the 6 component modified Sarnat exam as in the Neonatal Research Network of the National Institute of Child Health and Human Development trials of TH for moderate-severe encephalopathy and will be expanded to include features of mild encephalopathy. Eligible subjects must demonstrate ≥ 2 exam abnormalities (mild, moderate, severe) but without evidence of moderate-severe encephalopathy (≥ 3 moderate or severe features). The primary outcome is neurodevelopmental outcome at 12-14 months of age. Secondary outcomes include evaluating the safety profile of therapeutic hypothermia in patients with Mild HIE. Therapeutic hypothermia is well tolerated and did not demonstrate serious safety concerns when evaluated in multiple large studies of neonates with moderate-severe HIE. It is now being applied by some practitioners to neonates with Mild HIE without systematic evidence of benefit or potential harm. This data will be necessary in order to develop and larger trial of efficacy to be determined at 2 years of age. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04176471
Study type	Interventional
Source	Stanford University
Contact	Sonia L Bonifacio, MD
Phone	650-723-5711
Email	soniab1@stanford.edu
Status	Not yet recruiting
Phase	N/A
Start date	May 1, 2020
Completion date	January 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05471336` - Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)	N/A
Recruiting	`NCT05514340` - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy	Phase 2
Recruiting	`NCT04603547` - Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy
Completed	`NCT01913340` - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)	Phase 1/Phase 2
Completed	`NCT00581581` - CoolCap Followup Study-Coordination of Participating Centers	N/A
Recruiting	`NCT05772416` - Neonatal Neurological Examination to Detect Infants at Risk
Completed	`NCT03122808` - Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study
Recruiting	`NCT02544100` - Neonatal Neurologic Intensive Care Network of China
Completed	`NCT03380013` - OMT to Improve Feeding After Hypothermia	N/A
Active, not recruiting	`NCT03409770` - Optimising the Duration of Cooling in Mild Encephalopathy	N/A
Recruiting	`NCT05127070` - Evaluating the NeoTree in Malawi and Zimbabwe
Not yet recruiting	`NCT06098833` - Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia	Phase 2
Not yet recruiting	`NCT05756296` - The Long-term Consequences of Neonatal Encephalopathy in the Hypothermia Era
Recruiting	`NCT04432662` - Darbepoetin in Neonatal Encephalopathy Trial	Phase 2
Recruiting	`NCT02793999` - Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
Not yet recruiting	`NCT05889507` - Cooling in Mild Encephalopathy	N/A
Recruiting	`NCT05848271` - Natural History Study of Patients With HPDL Mutations
Completed	`NCT01309711` - Magnetic Resonance Biomarkers in Neonatal Encephalopathy
Recruiting	`NCT04225975` - Neonate Cerebral Activity in Immediate Post Partum	N/A
Recruiting	`NCT05610085` - A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy — TIME

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms